NCT03322475Unknown不适用
Evaluation of the Efficacy and Safety of PiQo4 for Facial Skin Rejuvenation
适应症
干预措施
试验速览
- 阶段
- 不适用
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Fitzpatrick Elastosis Score (FES) scale
研究概览
简要总结
A total of at least 20 healthy subjects at a single site, with at least two facial sub-areas with visible wrinkles with pigmentation and/or acne scars who wish to improve their skin appearance will be enrolled into the study. subjects will receive 3 treatments and return to follow-up visits at 1, 3, and 6 months following the last treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects must meet all of the following inclusion criteria to be entered into the study:
- •Healthy Female/Male.
- •Age= 18-70 (Adults).
- •Fitzpatrick skin phototype = I-V
- •Exhibiting at least two facial sub-areas with visible wrinkles with pigmentation and/or acne scars.
- •Able to read, understand and provide written Informed Consent.
- •Able and willing to comply with the treatment/follow-up schedule and post treatment care
- •Willingness to provide a brief medical history including disclosure of any prescribed or over-the-counter medications taken within the past 6 months.
- •Willingness to allow Focus Medical (the study Sponsor) and Lumenis and the investigators to use de-identified photographs of the treated area for presentation and publication purposes.
- •Daily use of sunscreen for the duration of the study
- •Women of child-bearing potential are required to use a reliable method of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, NuvaRing, partner with vasectomy, Implanon or other FDA-approved devices, or abstinence) during the course of the study.
排除标准
- •Any of the following will exclude the subject from the study:
- •Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 3 months after completion of breastfeeding
- •Prior skin laser, light or other energy device treatment in treated area within 6 months of initial treatment or during the course of the study.
- •Known hypersensitivity or contraindications to anesthetic agents including lidocaine and its derivatives, and Toradol.
- •Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treated area, unless treatment is conducted following a prophylactic regimen.
- •History of post inflammatory pigmentary disorders, particularly a tendency for hyper- or hypo-pigmentation.
- •Having Melasma.
- •Having multiple dysplastic Nevi in are to be treated.
- •Having an excessive underlying vascular conditions (e.g. dense network of capillaries).
- •History of keloid scarring or of abnormal wound healing.
- •Suffering from current or history of significant skin conditions in the treated area or inflammatory skin conditions.
- •History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
- •Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician's discretion).
- •Having a neurological disorder (including Multiple Sclerosis, Parkinson's disease).
- •Having seizure disorder.
- •Having fibromyalgia.
- •Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
- •Participation in a study of another device or drug within three months prior to enrolment or during the study.
- •Significant concurrent illness (e.g. uncontrolled diabetes) or any disease state that in the opinion of the Investigator would interfere with the treatment or healing process
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
- •Subjects who are opposed to possible damage to the hair follicles with possible loss of hair in the treatment area.
- •Received the following treatments in the area of the face to be treated during or within the noted timeframes prior to the study treatment:
- •Dermabrasion or chemical peel treatment within 3 months.
- •Any devices and/or Botox treatment within 6 months.
- •Collagen/fat injections or other methods of augmentation with injected or implanted material in the treated area within 9 months.
- •Resurfacing procedure, face lift or eyelid surgery within a year.
- •Having a permanent implant in the facial skin area, such as an injected chemical substance.
- •Any other surgery in treated area within 9 months of initial treatment or during the course of the study
- •Use of retinoids, antioxidants or therapeutic skin nourishing supplements at medicinal concentration within 2 months and oral retinoids within 6 months of the study
研究组 & 干预措施
Facial skin rejuvenation
Experimental
Facial skin rejuvenation using PiQo4 laser system
干预措施: PiQo4 laser system (Device)
结局指标
主要结局
Fitzpatrick Elastosis Score (FES) scale
时间窗: Baseline, 1 month follow up
Fine lines/wrinkles and elastosis improvement will be classified by the Fitzpatrick-Goldman Elastosis and Wrinkles scales: Class I, Class II or Class III.
Overall Global Aesthetic Improvement (GAI) Scale
时间窗: Baseline, 1 month follow up
The global aesthetic improvement (GAI) scale will be used by the investigator to grade improvement in the following categories: 1) Fine lines/wrinkles; 2) texture 3) Pigmentation 4) Acne scars. Score 0-Worse, Score 1-No Change, Score 2- Somewhat improved, Score 3- Moderately improved, Score 4-Very Much Improved.
次要结局
- Fitzpatrick Elastosis Score (FES) scale(Baseline, 3 month follow up)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)SchizophreniaNCT03565068Merck Sharp & Dohme LLC75
已完成
2 期
Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in VolunteersInfluenzaNCT03849560NPO Petrovax612
已完成
2 期
Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal VolunteersAnesthesiaNCT02908620Cetylite Industries40
已完成
1 期
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical CystectomyUrinary Bladder NeoplasmsNCT03404791Janssen Research & Development, LLC35
进行中（未招募）
1 期
AEUCTR2016-002455-20-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)